Other laboratories have used similar models to identify c-Met as a marker for PC stem cells [47], to evaluate the drug sensitivity of PC stem cells [48], or to use gene signatures to predict the response of PC patient-derived in vivo models to specific cytotoxic agents [49]. This evidence concerns the gene MET and pachyonychia congenita.